Dr. Alter Discusses the Immunotherapy Provenge

Robert S. Alter, MD
Published: Friday, Nov 11, 2011

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, describes the immunotherapy Provenge (sipuleucel-T) as a state-of-the-art breakthrough in the way prostate cancer patients are treated.

Vaccine therapies, such as Provenge, utilize the patient's immune system to fight tumor cells. In comparison to standard chemotherapy and newer targeted therapies Provenge has fewer toxicities and is better tolerated. The drug is a very short coursed therapy that does not subject patients to taking medications on a daily basis, which prevents many of the common toxicities that accompany daily doses of chemotherapy.

Alter describes Provenge as a durable therapy that effectively improves quality-of-life for patients.

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, describes the immunotherapy Provenge (sipuleucel-T) as a state-of-the-art breakthrough in the way prostate cancer patients are treated.

Vaccine therapies, such as Provenge, utilize the patient's immune system to fight tumor cells. In comparison to standard chemotherapy and newer targeted therapies Provenge has fewer toxicities and is better tolerated. The drug is a very short coursed therapy that does not subject patients to taking medications on a daily basis, which prevents many of the common toxicities that accompany daily doses of chemotherapy.

Alter describes Provenge as a durable therapy that effectively improves quality-of-life for patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x